File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1097/JTO.0b013e3181b28f15
- Scopus: eid_2-s2.0-69549116225
- PMID: 19704339
- WOS: WOS:000269495500018
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Capecitabine as salvage treatment for lymphoepithelioma-like carcinoma of lung
Title | Capecitabine as salvage treatment for lymphoepithelioma-like carcinoma of lung |
---|---|
Authors | |
Keywords | 5-Fluorouracil Capecitabine Lymphoepithelioma-like carcinoma |
Issue Date | 2009 |
Publisher | Lippincott Williams & Wilkins. |
Citation | Journal Of Thoracic Oncology, 2009, v. 4 n. 9, p. 1174-1177 How to Cite? |
Abstract | Lymphoepithelioma-like carcinoma (LELC) of lung has previously demonstrated good clinical response to 5-fluorouracil containing chemotherapy regimen, similar to the observation in undifferentiated nasopharyngeal carcinoma. Capecitabine, which is converted into active 5-fluorouracil within tumor cells, has been found effective in colorectal, breast, and recently nasopharyngeal carcinomas. We report our experience in five patients with advanced or metastatic LELC of lung who were treated with single agent capecitabine as salvage chemotherapy. The finding of disease control in three of five patients, especially with exceptionally durable stable disease (14.8 months) in one patient, suggests the potential clinical activity of capecitabine in LELC of lung. Future studies on capecitabine-containing chemotherapy regimens in LELC of lung are warranted. © 2009 International Association for the Study of Lung Cancer. |
Persistent Identifier | http://hdl.handle.net/10722/77781 |
ISSN | 2023 Impact Factor: 21.0 2023 SCImago Journal Rankings: 7.879 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ho, JC | en_HK |
dc.contributor.author | Lam, DC | en_HK |
dc.contributor.author | Wong, MK | en_HK |
dc.contributor.author | Lam, B | en_HK |
dc.contributor.author | Ip, MS | en_HK |
dc.contributor.author | Lam, WK | en_HK |
dc.date.accessioned | 2010-09-06T07:35:39Z | - |
dc.date.available | 2010-09-06T07:35:39Z | - |
dc.date.issued | 2009 | en_HK |
dc.identifier.citation | Journal Of Thoracic Oncology, 2009, v. 4 n. 9, p. 1174-1177 | en_HK |
dc.identifier.issn | 1556-0864 | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/77781 | - |
dc.description.abstract | Lymphoepithelioma-like carcinoma (LELC) of lung has previously demonstrated good clinical response to 5-fluorouracil containing chemotherapy regimen, similar to the observation in undifferentiated nasopharyngeal carcinoma. Capecitabine, which is converted into active 5-fluorouracil within tumor cells, has been found effective in colorectal, breast, and recently nasopharyngeal carcinomas. We report our experience in five patients with advanced or metastatic LELC of lung who were treated with single agent capecitabine as salvage chemotherapy. The finding of disease control in three of five patients, especially with exceptionally durable stable disease (14.8 months) in one patient, suggests the potential clinical activity of capecitabine in LELC of lung. Future studies on capecitabine-containing chemotherapy regimens in LELC of lung are warranted. © 2009 International Association for the Study of Lung Cancer. | en_HK |
dc.language | eng | en_HK |
dc.publisher | Lippincott Williams & Wilkins. | en_HK |
dc.relation.ispartof | Journal of Thoracic Oncology | en_HK |
dc.rights | Journal of Thoracic Oncology. Copyright © Lippincott Williams & Wilkins. | en_HK |
dc.subject | 5-Fluorouracil | - |
dc.subject | Capecitabine | - |
dc.subject | Lymphoepithelioma-like carcinoma | - |
dc.subject.mesh | Aged | en_HK |
dc.subject.mesh | Carcinoma, Non-Small-Cell Lung - drug therapy | en_HK |
dc.subject.mesh | Deoxycytidine - analogs & derivatives - therapeutic use | en_HK |
dc.subject.mesh | Disease Progression | en_HK |
dc.subject.mesh | Female | en_HK |
dc.subject.mesh | Fluorouracil - analogs & derivatives - therapeutic use | en_HK |
dc.subject.mesh | Humans | en_HK |
dc.subject.mesh | Lung Neoplasms - drug therapy | en_HK |
dc.subject.mesh | Male | en_HK |
dc.subject.mesh | Middle Aged | en_HK |
dc.subject.mesh | Salvage Therapy | en_HK |
dc.title | Capecitabine as salvage treatment for lymphoepithelioma-like carcinoma of lung | en_HK |
dc.type | Article | en_HK |
dc.identifier.openurl | http://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1556-0864&volume=4&issue=9&spage=1174&epage=1177&date=2009&atitle=Capecitabine+as+salvage+treatment+for+lymphoepithelioma-like+carcinoma+of+lung | en_HK |
dc.identifier.email | Ho, JC:jhocm@hku.hk | en_HK |
dc.identifier.email | Lam, DC:lamcl@hkucc.hku.hk | en_HK |
dc.identifier.email | Ip, MS:msmip@hku.hk | en_HK |
dc.identifier.authority | Ho, JC=rp00258 | en_HK |
dc.identifier.authority | Lam, DC=rp01345 | en_HK |
dc.identifier.authority | Ip, MS=rp00347 | en_HK |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1097/JTO.0b013e3181b28f15 | en_HK |
dc.identifier.pmid | 19704339 | - |
dc.identifier.scopus | eid_2-s2.0-69549116225 | en_HK |
dc.identifier.hkuros | 167339 | en_HK |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-69549116225&selection=ref&src=s&origin=recordpage | en_HK |
dc.identifier.volume | 4 | en_HK |
dc.identifier.issue | 9 | en_HK |
dc.identifier.spage | 1174 | en_HK |
dc.identifier.epage | 1177 | en_HK |
dc.identifier.eissn | 1556-1380 | - |
dc.identifier.isi | WOS:000269495500018 | - |
dc.publisher.place | United States | en_HK |
dc.identifier.scopusauthorid | Ho, JC=7402649981 | en_HK |
dc.identifier.scopusauthorid | Lam, DC=7201749615 | en_HK |
dc.identifier.scopusauthorid | Wong, MK=23480818200 | en_HK |
dc.identifier.scopusauthorid | Lam, B=9246012800 | en_HK |
dc.identifier.scopusauthorid | Ip, MS=7102423259 | en_HK |
dc.identifier.scopusauthorid | Lam, WK=7203021937 | en_HK |
dc.identifier.issnl | 1556-0864 | - |